Skip to main content
  • About Us
  • Image Credits
  • Contributor Info
  • RSS
  • Log In
  • Join
  • TwitterTwitter
  • E-Alerts
  • Visit StemJournal

Main menu

  • About
    • Image Credits
    • Contributor Info
    • E-Alerts
  • Chapters
    • Cellular and nuclear reprogramming
    • Ectoderm specification and differentiation
    • Endoderm specification and differentiation
    • Epigenetics
    • Genomics and proteomics
    • Germ cell and somatic stem cell biology in reproduction
    • Manufacturing
    • Mesoderm specification and differentiation
    • Niche biology, homing, and migration
    • Renewal
    • Stem cell immunology
    • Therapeutic prospects
    • Tissue engineering
  • Protocols
    • Ectoderm differentiation
    • Endoderm differentiation
    • Genome editing
    • Mesoderm differentiation
    • Pluripotent stem cells
    • PSC characterization
    • PSC genetic stability
    • Reprogramming
  • StemLabs
    • Stem Cell COREdinates
    • Core Facility Profiles
      • Boston Children's Hospital Human Neuron Core
      • Boston University Center for Regenerative Medicine iPSC Core
      • Columbia Stem Cell Initiative Stem Cell Core Facility
      • Harvard Stem Cell Institute iPS Core Facility
    • Stem Cell Protocols
    • Stem Cell Reagents
    • Other Resources
  • News & Profiles
    • Latest News
    • Stem Cell Institute Profiles
  • Journal Stream
  • Forum

    Search form

    You are here

    Home

    Biblio

    Author Title Type [ Year(Desc)]
    Filters: Author is Riedell, Peter A  [Clear All Filters]
    2020
    Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, Riedell PA, Bishop M, Liu H. Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation: Toxicities with maintenance nivolumab after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
    • PubMed
    • Google Scholar
    2021
    Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSubramania, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, et al. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021.
    • PubMed
    • Google Scholar
    2022
    Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022.
    • PubMed
    • Google Scholar
    Godfrey J, Liu H, Yu J, Tallarico M, Curran E, Artz AS, Riedell PA, Stock W, Karrison T, Fitzpatrick C, et al. Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation. Blood Adv. 2022.
    • PubMed
    • Google Scholar

    Disclaimer | Privacy Policy | StemBook is published by IOS Press, Copyright © 2021
    Copyright 2013 by the Massachusetts General Hospital. Some sections copyright 2008–2009 by The President and Fellows of Harvard College.

    IOS Press logoHSCI logoNIH logoMIND logo


    Creative Commons License
    All content unless otherwise noted is licensed under a Creative Commons Attribution 3.0 Unported License